GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aspen Pharmacare Holdings Ltd (OTCPK:APNHY) » Definitions » EBIT

Aspen Pharmacare Holdings (Aspen Pharmacare Holdings) EBIT : $431 Mil (TTM As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Aspen Pharmacare Holdings EBIT?

Aspen Pharmacare Holdings's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was $209 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $431 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aspen Pharmacare Holdings's annualized ROC % for the quarter that ended in Dec. 2023 was 4.81%. Aspen Pharmacare Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 20.41%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aspen Pharmacare Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 6.85%.


Aspen Pharmacare Holdings EBIT Historical Data

The historical data trend for Aspen Pharmacare Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspen Pharmacare Holdings EBIT Chart

Aspen Pharmacare Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 313.88 341.42 517.07 562.72 420.33

Aspen Pharmacare Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 291.85 269.44 214.93 222.20 209.20

Competitive Comparison of Aspen Pharmacare Holdings's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspen Pharmacare Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aspen Pharmacare Holdings's EV-to-EBIT falls into.



Aspen Pharmacare Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $431 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aspen Pharmacare Holdings  (OTCPK:APNHY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aspen Pharmacare Holdings's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=375.682 * ( 1 - 20.43% )/( (6184.488 + 6255.474)/ 2 )
=298.9301674/6219.981
=4.81 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7163.8 - 397.177 - ( 582.135 - max(0, 1234.902 - 2373.992+582.135))
=6184.488

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7475.634 - 597.709 - ( 622.451 - max(0, 1231.377 - 2362.34+622.451))
=6255.474

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Aspen Pharmacare Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=418.402/( ( (1008.12 + max(906.439, 0)) + (1054.055 + max(1131.016, 0)) )/ 2 )
=418.402/( ( 1914.559 + 2185.071 )/ 2 )
=418.402/2049.815
=20.41 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(538.123 + 1045.943 + 135.451) - (397.177 + 0 + 415.901)
=906.439

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(673.865 + 1017.346 + 48.678) - (597.709 + 0 + 11.164)
=1131.016

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Aspen Pharmacare Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=431.396/6293.700
=6.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aspen Pharmacare Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Aspen Pharmacare Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspen Pharmacare Holdings (Aspen Pharmacare Holdings) Business Description

Traded in Other Exchanges
Address
Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF
Aspen Pharmacare Holdings Ltd is a specialty pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both API and finished dose form. The company focuses on a broad range of post-patent, branded medicines and domestic brands spanning many therapeutic areas. The company has four business segments such as Active Pharmaceutical Ingredients (API) - this segment includes the API Chemicals business and non-heparin biochemical API business, Heparin - this segment includes the full value chain contribution from all heparin containing products including API and Finished Dose. Form (FDF) sales Key products include the Fraxiparine and MonoEmbolex heparin containing FDF products and FDF Steriles segment.

Aspen Pharmacare Holdings (Aspen Pharmacare Holdings) Headlines

From GuruFocus

Value Idea Contest: Aspen Pharmacare

By Matthew Sipos Matthew Sipos 03-17-2019